Diabetes mellitus, preexisting coronary heart disease, and the risk of subsequent coronary heart disease events in patients infected with human immunodeficiency virus the data collection on adverse events of anti-HIV drugs (D:A:D Study)

Circulation

Volumn 119, Issue 6, 2009, Pages 805-811

  Worm, Signe W ^a,k   De Wit, Stephane ^b   Weber, Rainer ^c   Sabin, Caroline A ^d   Reiss, Peter ^e   El Sadr, Wafaa ^f   D'Arminio Monforte, Antonella ^g   Kirk, Ole ^a   Fontas, Eric ^h   Dabis, Francois ⁱ   Law, Matthew G ^j   Lundgren, Jens D ^a   Friis Møller, Nina ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b SAINT PIERRE UNIVERSITY HOSPITAL   (Belgium)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e STICHTING HIV MONITORING   (Netherlands)

^f Och Spine at New York Presbyterian Hospitals   (United States)

^g UNIVERSITY OF MILAN   (Italy)

^h CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

ⁱ INSERM   (France)

^j UNIVERSITY OF NEW SOUTH WALES   (Australia)

^k UNIVERSITY OF COPENHAGEN   (Denmark)

more..

Author keywords

Coronary disease; Diabetes mellitus; Epidemiology; Human immunodeficiency virus; Risk factors

Indexed keywords

ADULT; AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE TRANSMISSION; ETHNICITY; FAMILY HISTORY; FEMALE; GROUPS BY AGE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; POISSON DISTRIBUTION; PRIORITY JOURNAL; RISK FACTOR; SEX DIFFERENCE; SMOKING;

ADULT; AGE FACTORS; ANTI-HIV AGENTS; CORONARY DISEASE; DIABETES COMPLICATIONS; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; RECURRENCE; RISK FACTORS;

EID: 61949441350     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.108.790857     Document Type: Article

References (43)

1. Executive summary of the third report of the National Cholesterol Educational Program (NCEP) expert panel on detection, evaluation and treatment of high cholesterol in adults (Adult Treatment Panel III). JAMA. 2005;285:2486-2497.
2. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339:229-234.
3. Malmberg K, Yusuf S, Gerstein HC, Brown J, Zhao F, Hunt D, Piegas L, Calvin J, Keltai M, Budaj A. Impact of diabetes on long-term prognosis in patients with unstable angina and non-Q-wave myocardial infarction: results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) Registry. Circulation. 2000;102:1014-1019.
4. Schramm TK, Gislason GH, Kober L, Rasmussen S, Rasmussen JN, Abildstrom SZ, Hansen ML, Folke F, Buch P, Madsen M, Vaag A. Torp-Pedersen C. Diabetes patients requiring glucose-lowering therapy and nondiabetics with a prior myocardial infarction carry the same cardiovascular risk: a population study of 3.3 million people. Circulation. 2008;117:1945-1954.
5. Juutilainen A, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Type 2 diabetes as a "coronary heart disease equivalent": an 18-year prospective population-based study in Finnish subjects. Diabetes Care. 2005;28: 2901-2907.
6. Lee CD, Folsom AR, Pankow JS, Brancati FL. Cardiovascular events in diabetic and nondiabetic adults with or without history of myocardial infarction. Circulation. 2004;109:855-860.
7. Evans JM, Wang J, Morris AD. Comparison of cardiovascular risk between patients with type 2 diabetes and those who had had a myocardial infarction: cross sectional and cohort studies. BMJ. 2002;20: 939-942.
8. Lotufo PA, Gaziano JM, Chae CU, Ajani UA, Moreno-John G, Buring JE, Manson JE. Diabetes and all-cause and coronary heart disease mortality among US male physicians. Arch Intern Med. 2001;22:242-247.
9. Cho E, Rimm EB, Stampfer MJ, Willett WC, Hu FB. The impact of diabetes mellitus and prior myocardial infarction on mortality from all causes and from coronary heart disease in men. J Am Coll Cardiol. 2002;40:954-960.
10. Noor MA, Seneviratne T, Aweeka FT, Lo JC, Schwarz, JM, Mulligan K, Schambelan M, Grunfeld C. Indinavir acutely inhibits insulin-stimulated glucose disposal in humans: a randomized, placebo-controlled study. AIDS. 2002;29:F1-F8.
11. Lee GA, Lo JC, Aweeka F, Schwarz JM, Mulligan K, Schambelan M, Grunfeld C. Single-dose lopinavir-ritonavir acutely inhibits insulin-mediated glucose disposal in healthy volunteers. Clin Infect Dix. 2006; 43:658-660.
12. De Wit S, Sabin CA, Weber R, Worm SW, Reiss P, Cazanave C, El-Sadr W, Monforte AD, Fontas E, Law MG, Friis-Moller N, Lundgren JD. Incidence and risk factors for new-onset diabetes in HIV-infected patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study. Diabetes Care. 2008;31:1224-1229.
13. Brown TT, Li X, Cole SR, Kingsley LA, Patella FJ, Riddler SA, Chmiel JS, Visscher BR, Margolick JB, Dobs AS. Cumulative exposure to nucleoside analogue reverse transcriptase inhibitors is associated with insulin resistance markers in the Multicenter AIDS Cohort Study. AIDS. 2005;2:1375-1383.
14. Carr A, Samaras K, Chisholm DJ, Cooper DA. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet. 1998;20:1881-1883.
15. Hadigan C, Meigs JB, Corcoran C. Rietschel P. Piecuch S, Basgoz N, Davis B, Sax P, Stanley T, Wilson PW, D'Agostino RB, Grinspoon S. Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin Infect Dis. 2001;32:130-139.
16. van der VaIk M, Bisschop PH, Romijn JA, Ackemanns MT, Lange JM. Endert E, Reiss P, Sauerwein HP. Lipodystrophy in HIV-1-positive patients is associated with insulin resistance in multiple metabolic pathways. AIDS. 2001;15:2093-100.
17. Friis-Moller N, Weber R, Reiss P, Thiebaut R, Kirk O, d'Arminio Monforte A, Pradier C, Morfeldt L, Mateu S, Law M. El-Sadr W, De Wit S, Sabin CA, Phillips AN, Lundgren JD. Cardiovascular disease risk factors in HIV patients: association with antiretroviral therapy: results from the DAD study. AIDS. 2003;23:1179-1193.
18. Glass TR, Ungsedhapand C, Wolbers M, Weber R. Vernazza PL. Rickenbach M, Furrer H, Cavassini M, Hirschel B. Battegay M, Bucher HC. Prevalence of risk factors for cardiovascular disease in HIV-infected patients over time: the Swiss HIV Cohort Study. HIV Med. 2006;7: 404-410.
19. Santos J, Palacios R, Gonzalez M, Ruiz J, Marquez M. Atherogenic lipid profile and cardiovascular risk factors in HIV-infected patients (Netar Study). Int J STD AIDS. 2005;16:677-680.
20. Grinspoon S, Grunfeld C, Kotler D, Currier JS. Lundgren JD, Dube MP, Lipschultz SE, Hsue P, Squires K, Schambelan M. Wilson PW, Yarasheski K, Hadigan C, Stein JH, Eckel RH. Executive summary, state of the science conference: initiative to decrease cardiovascular risk and increase quality of care for patients living with HIV/AIDS. Circulation. 2008;118:198-210.
21. Iloeje UH. Yuan Y, L'italien G, Mauskopf J, Holmberg SD, Moorman AC, Wood KC, Moore RD. Protease inhibitor exposure and increased risk of cardiovascular disease in HIV-infected patients. HIV Med. 2005;6: 37-44.
22. Friis-Moller N, Sabin CA, Weber R, Monforte AD, El-Sadr WM. Reiss P, Thiebaut R, Morfeldt L, De Wit S, Pradier C, Calvo G, Law MG, Kirk O, Phillips AN, Lundgren JD. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med. 2003;349:1993-2003.
23. Friis-Moller N, Reiss P, Sabin CA, Weber R. Monforte AD. El-Sadr W, Thiebaut R, De Wit S, Kirk O, Fontas E, Law MG, Phillips A, Lundgren JD. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med. 2007;356:1723-1735.
24. d'Arminio A, Sabin CA, Phillips AN, Reiss P, Weber R, Kirk O, El-Sadr W, De Wit S, Mateu S, Petoumenos K, Dabis F, Pradier C, Morfeldt L, Lundgren JD, Friis-Moller N. Cardio- and cerebrovascular events in HIV-infected persons. AIDS. 2004;18:1811-1817.
25. Carr A. Samaras K, Burton S, Law M, Freund J. Chisholm DJ, Cooper DA. A syndrome of peripheral lipodystrophy. hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS. 1998;12:F51-F58.
26. Hertel J, Struthers H, Horj CB, Hruz PW. A structural basis for the acute effects of HIV protease inhibitors on GLUT4 intrinsic activity. J Biol Chem. 2004;279:55147-55152.
27. Kakuda TN. Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity. Clin Ther. 2000;22: 685-708.
28. Fleischman A, Johnsen S, Systrom DM, Hrovat M, Farrar CT, Frontera W, Fitch K, Thomas BJ, Torriani M, Cote HC, Grinspoon SK. Effects of a nucleoside reverse transcriptase inhibitor, stavudine, on glucose disposal and mitochondrial function in muscle of healthy adults. Am J Physiol Endocrinol Metab. 2007;292:E1666-E1673.
29. Blumer RM, van Vonderen MG, Sutinen J, Hassink E, Ackermans M, van Agtmael MA, Yki-Jarvinen H, Danner SA, Reiss P, Sauerwein HP. Zidovudine/lamivudine contributes to insulin resistance within 3 months of starting combination antiretroviral therapy, AIDS. 2008;22:227-236.
30. Mondy K, Overton ET, Grubb J, Tong S, Seyfried W, Powderly W, Yarasheski K. Metabolic syndrome in HIV-infected patients from an urban, midwestern US outpatient population. Clin Infect Dis. 2007;44: 726-734.
31. Saves M, Chene G, Ducimetiere P, Leport C, Le Moal G, Amouyel P, Arveiler D, Ruidavets JB, Reynes J, Bingham A, Raffi F. Risk factors for coronary heart disease in patients treated for human immunodeficiency virus infection compared with the general population. Clin Infect Dis. 2003;37:292-298.
32. Soriano V, Mocroft A, Ledergerber B, Knysz B, Chaplinas S, Katlama C, Vogel M, Rockstroh JK, Lundgren J; on behalf of the EuroSIDA Study. Epidemiological and virological characteristics of chronic hepatitis C (HCV) within the EuroSIDA observational cohort. Presented at: 11th European AIDs Conference/EACS Madrid; October 24-27, 2007; Madrid, Spain. PS 8.1.
33. Weber R, Sabin C, Reiss P, De Wit S, Worm SW, Law M, Dabis F, d'Arminio Monforte A, Fontas E, Friis-Moller N, El-Sadr W, Kirk O, Lundgren JD; on behalf of the DAD Study. Hepatitis virus co-infections and risk of diabetes mellitus (DM) and myocardial infarction (MI) in HIV-infected persons: the D:A:D Study. Presented at: 15th Conference on Retroviruses and Opportunistic Infections (CROI); February 3-6, 2008; Boston, Mass. No. 133.
34. Vaccaro O, Eberly LE, Neaton JD, Yang L, Riccardi G, Stamler J, Impact of diabetes and previous myocardial infarction on long-term survival: 25-year mortality follow-up of primary screenees of the Multiple Risk Factor Intervention Trial. Arch Intern Med. 2004;164:1438-1443.
35. Hu FB, Stampfer MJ, Solomon CG, Liu S, Willett WC, Speizer FE, Nathan DM, Manson JE. The impact of diabetes mellitus on mortality from all causes and coronary heart disease in women: 20 years of follow-up. Arch Intern Med. 2001;23:1717-1723.
36. Becker A, Bos G, de Vegt F, Kostense PJ, Dekker JM, Nijpels G, Heine RJ, Bouter LM, Stehouwer CD. Cardiovascular events in type 2 diabetes: comparison with nondiabetic individuals without and with prior cardiovascular disease: 10-year follow-up of the Hoorn Study. Eur Heart J. 2003;24:1406-1413.
37. Hu FB. The impact of diabetes and prediabetes on risk of cardiovascular disease and mortality. Drugs Today (Barc). 2002;38:769-775.
38. Fox CS, Sullivan L, D'Agostino RB Sr, Wilson PW. The significant effect of diabetes duration on coronary heart disease mortality: the Framingham Heart Study. Diabetes Care. 2004;27:704-708.
39. Mukamal KJ, Nesto RW, Cohen MC, Muller JE, Maclure M, Sherwood JB, Mittleman MA. Impact of diabetes on long-term survival after acute myocardial infarction: comparability of risk with prior myocardial infarction. Diabetes Care. 2001;24:1422-1427.
40. Sabin CA, Weber R, Fontas E, Dabis F, Wit SD, Worm SW, Reiss R, Monforte AD, Friis-Møller N, Lundgren JD. Underutilisation of recommended interventions for the prevention of coronary heart disease (CHD) in HIV-infected patients with established cardiovascular disease or diabetes mellitus: results from a multi-cohort study. Presented at: Conference on Retroviruses and Opportunistic Infections (CROI); February 25-28, 2007; Los Angeles, Calif. No. 816.
41. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2007;30:542-547.
42. Genuth S, Alberti KG, Bennett P, Buse J, Defronzo R, Kahn R, Kitzmiller J, Knowler WC, Lebovitz H, Lernmark A, Nathan D, Palmer J, Rizza R, Saudek C, Shaw J, Steffes M, Stern M, Tuomilehto J, Zimmet P. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care. 2003;26:3160-3167.
43. Sabin CA, d'Arminio Monforte A, Friis-Moller N, Weber R, El-Sadr W, Reiss P, Kirk O, Mercie P, Law MG, De Wit S, Pradier C, Phillips AN, Lundgren JD. Changes over time in risk factors for cardiovascular disease and use of lipid-lowering drugs in HIV-infected individuals and impact on myocardial infarction. Clin Infect Dis. 2008;46:1101-1110.